(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Metastatic Breast Cancer pipeline constitutes 7+ key companies continuously working towards developing 8+ Metastatic Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Metastatic Breast Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Breast Cancer Market.
The Metastatic Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Metastatic Breast Cancer Pipeline Report:
- Companies across the globe are diligently working toward developing novel Metastatic Breast Cancer treatment therapies with a considerable amount of success over the years.
- Metastatic Breast Cancer companies working in the treatment market are Phoenix Molecular Designs, Dantari, Inc., Daiichi Sankyo Co., Ltd., Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S., Jiangsu HengRui Medicine Co., Ltd., Genor Biopharma Co., Ltd, RemeGen, SynCore Biotechnology, Byondis B.V., Sichuan Baili Pharmaceutical Co., Ltd., Allarity Therapeutics, Kind Pharmaceuticals LLC, Shanghai Miracogen Inc., Phoenix Molecular Designs, and others, are developing therapies for the Metastatic Breast Cancer treatment
- Emerging Metastatic Breast Cancer therapies such as – PMD-026, DAN-222, Patritumab Deruxtecan, Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant, Disitamab Vedotin, EndoTAG®-1 (SB05), trastuzumab duocarmazine, GNC 035, Stenoparib (2X-121), HS-10342, AND019, MRG002, PMD-026, and others are expected to have a significant impact on the Metastatic Breast Cancer market in the coming years.
- On May 04, 2022, At the ESMO Breast Cancer Meeting, which will be held in Berlin, Germany from May 3-5, 2022, Rhizen Pharmaceuticals AG said that it would present encouraging interim data from a Ph2 trial of Tenalisib that is currently being conducted in patients with locally advanced or metastatic breast cancer. In both primary and secondary resistant mBC, tenalisib was well tolerated and had good preliminary efficacy as a single drug. The available data encourage future tenalisib development for patients with HR+ and HER2- MBC
- In April 2022, Data from the phase II clinical research of the chemo-free regimen of KN026 combined with KN046 (KN026-203), according to an announcement from Alphamab Oncology, were presented as an E-poster at the AACR Annual Meeting 2022 (AACR 2022). As of August 10, 2021, there were 24 patients enrolled, 20 of whom could be evaluated for overall response: the ORR was 55.0%, the DCR was 85.0%, and the 6-month PFS rate was 84.1%; of the 11 CRC patients who could be evaluated, the ORR and DCR were 45.5% and 90.9%, respectively. These patients had other solid tumours that were HER2-positive but not breast or gastric cancer
- In April 2022, The I-SPY 2.2 TRIAL for the treatment of HER2-positive breast cancer in the neoadjuvant setting has chosen Ambrx Biopharma Inc.’s antibody-drug conjugate (ADC) ARX788 as a new experimental treatment arm, according to Quantum Leap Healthcare CollaborativeTM (Quantum Leap) and Ambrx Biopharma Inc. The I-SPY 2.2 TRIAL, sponsored by Quantum Leap, is a follow-up to the I-SPY 2 TRIAL and aims to develop personalised treatments by customising therapies for each patient to improve the clinical result
- In September 2021, A Phase III clinical research using GB491 and Fulvestrant in patients with HR+, HER2-positive locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy was started by Genor Biopharma
Metastatic Breast Cancer Overview
Breast cancer that has migrated to another body site, most frequently the bones, lungs, brain, or liver, is referred to as metastatic breast cancer, also known as stage IV. Even after the initial diagnosis and treatment, breast cancer can return in another area of the body months or even years later. This is referred to as a distant or metastatic recurrence. Nearly 30% of women with breast cancer in the early stages develop metastatic illness.
Get a Free Sample PDF Report to know more about Metastatic Breast Cancer Pipeline Therapeutic Assessment
Emerging Metastatic Breast Cancer Drugs Under Different Phases of Clinical Development Include:
- PMD-026: Phoenix Molecular Designs
- DAN-222: Dantari, Inc.
- Patritumab Deruxtecan: Daiichi Sankyo Co., Ltd.
- Tenalisib: Rhizen Pharmaceuticals SA
- OP-1250: Olema Oncology
- Eftilagimod alpha: Immutep S.A.S.
- SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
- GB491+ Fulvestrant : Genor Biopharma Co., Ltd
Route of Administration
Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Metastatic Breast Cancer Pipeline Therapeutics Assessment
- Metastatic Breast Cancer Assessment by Product Type
- Metastatic Breast Cancer By Stage and Product Type
- Metastatic Breast Cancer Assessment by Route of Administration
- Metastatic Breast Cancer By Stage and Route of Administration
- Metastatic Breast Cancer Assessment by Molecule Type
- Metastatic Breast Cancer by Stage and Molecule Type
DelveInsight’s Metastatic Breast Cancer Report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Metastatic Breast Cancer product details are provided in the report. Download the Metastatic Breast Cancer pipeline report to learn more about the emerging Metastatic Breast Cancer therapies
Some of the key companies in the Metastatic Breast Cancer Therapeutics Market include:
Key companies developing therapies for Metastatic Breast Cancer are – RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Ltd., and others.
Metastatic Breast Cancer Pipeline Analysis:
The Metastatic Breast Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Breast Cancer Treatment.
- Metastatic Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Breast Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Metastatic Breast Cancer drugs and therapies
Metastatic Breast Cancer Pipeline Market Drivers
- Increasing prevalence of breast cancer, launch of several diagnostic and screening programs are some of the important factors that are fueling the Metastatic Breast Cancer Market.
Metastatic Breast Cancer Pipeline Market Barriers
- However, high cost associated with the treatment, several side effects associated with the use of breast cancer therapeutics and other factors are creating obstacles in the Metastatic Breast Cancer Market growth.
Scope of Metastatic Breast Cancer Pipeline Drug Insight
- Coverage: Global
- Key Metastatic Breast Cancer Companies: Phoenix Molecular Designs, Dantari, Inc., Daiichi Sankyo Co., Ltd., Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S., Jiangsu HengRui Medicine Co., Ltd., Genor Biopharma Co., Ltd, RemeGen, SynCore Biotechnology, Byondis B.V., Sichuan Baili Pharmaceutical Co., Ltd., Allarity Therapeutics, Kind Pharmaceuticals LLC, Shanghai Miracogen Inc., Phoenix Molecular Designs, and others
- Key Metastatic Breast Cancer Therapies: PMD-026, DAN-222, Patritumab Deruxtecan, Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant, Disitamab Vedotin, EndoTAG®-1 (SB05), trastuzumab duocarmazine, GNC 035, Stenoparib (2X-121), HS-10342, AND019, MRG002, PMD-026, and others
- Metastatic Breast Cancer Therapeutic Assessment: Metastatic Breast Cancer current marketed and Metastatic Breast Cancer emerging therapies
- Metastatic Breast Cancer Market Dynamics: Metastatic Breast Cancer market drivers and Metastatic Breast Cancer market barriers
Request for Sample PDF Report for Metastatic Breast Cancer Pipeline Assessment and clinical trials
Table of Contents
| 1 | Metastatic Breast Cancer Report Introduction |
| 2 | Metastatic Breast Cancer Executive Summary |
| 3 | Metastatic Breast Cancer Overview |
| 4 | Metastatic Breast Cancer- Analytical Perspective In-depth Commercial Assessment |
| 5 | Metastatic Breast Cancer Pipeline Therapeutics |
| 6 | Metastatic Breast Cancer Late Stage Products (Phase II/III) |
| 7 | Metastatic Breast Cancer Mid Stage Products (Phase II) |
| 8 | Metastatic Breast Cancer Early Stage Products (Phase I) |
| 9 | Metastatic Breast Cancer Preclinical Stage Products |
| 10 | Metastatic Breast Cancer Therapeutics Assessment |
| 11 | Metastatic Breast Cancer Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Metastatic Breast Cancer Key Companies |
| 14 | Metastatic Breast Cancer Key Products |
| 15 | Metastatic Breast Cancer Unmet Needs |
| 16 | Metastatic Breast Cancer Market Drivers and Barriers |
| 17 | Metastatic Breast Cancer Future Perspectives and Conclusion |
| 18 | Metastatic Breast Cancer Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Latest Reports:
Vascular Graft Devices Market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028.
Vascular Stents Market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028.
Ventricular Assist Devices Market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028.
Resorbable Vascular Scaffolds Market
DelveInsight’s ‘Resorbable Vascular Scaffolds – Market Insight, Competitive Landscape and Market Forecast, 2028’ report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market
DelveInsight’s ‘Vein Illumination Devices – Market Insight, Competitive Landscape and Market Forecast, 2028’ report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Monkeypox Market
DelveInsight’s “Monkeypox Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Pars Planitis Market
DelveInsight’s “Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Patient Monitoring Devices Market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.
Typhoid Market
DelveInsight’s “Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Zika Virus Market
DelveInsight’s “Zika Virus Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Related Reports by DelveInsight-
Gastric neuroendocrine tumours market | Bronchial spasms market | Wilms tumor market | Interbody cages market | Prefilled Syringes Market | Duchenne Muscular Dystrophy Market | Cardiac Amyloidosis Market | Encephalitis Market | Age-Related Macular Degeneration Market | Polycythemia Market | Myelofibrosis Market | Urolithiasis Market | Acute Coronary Syndrome Market | Lymphocytopenia Market | Minimal Residual Disease Market | Biliary Atresia Market | Surgical Site Infection Ssi Market | Thyroid Eye Disease Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Biochips Market | Neurovascular Devices Market | Idiopathic Pulmonary Fibrosis Market | 3d Cardiac Mapping System Market | Non Alcoholic Fatty Liver Disease Nafld Market | Complicated Intra-Abdominal Infections Market | Defibrillators Market | Anterior Cruciate Ligament Injuries Market | Intracranial Pressure Monitoring Devices Market | Adrenal Crisis Market | Cerebral Vein Thrombosis Market | Chemotherapy Induced Febrile Neutropenia Market | Refractory Angina Market | Ataxia Telangiectasia Market | Cardiac Insufficiency Market | Chronic Bronchitis Market | Diffuse Large B-Cell Lymphoma Market | Acrocallosal Syndrome Market | Dermal Mycosis Market | Achondroplasia Market | Opioid Induced Constipation Market | Hearing Aid Devices Market | Vertigo Market | Airway Stent Market Market | Chronic Lymphocytic Leukemia Market | Severe Hypoglycemia Market | Neuromodulation Devices Market | Cerebral Aneurysm Market | Pruritus Market | Scleroderma Market | Nsclc Market | Concussions Market Size
Recent Blog’s By DelveInsight:
- Insights Into The Cutaneous T-cell Lymphoma Treatment Market
- Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
- Emerging Role of Digital Health in the Field of Oncology
- How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
- How are Technological Trends and Innovations Reshaping the Dementia Care
- Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
- Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
- Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
- Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187